Triazolopyridazine LRRK2 kinase inhibitors

被引：25

作者：

Franzini, Maurizio ^{[1
]}

Ye, Xiaocong M. ^{[1
]}

Adler, Marc ^{[2
]}

Aubele, Danielle L. ^{[1
]}

Garofalo, Albert W. ^{[1
]}

Gauby, Shawn ^{[3
]}

Goldbach, Erich ^{[3
]}

Probst, Gary D. ^{[1
]}

Quinn, Kevin P. ^{[3
]}

Santiago, Pam ^{[3
]}

Sham, Hing L. ^{[1
]}

Tam, Danny ^{[4
]}

Anh Truong ^{[1
]}

Ren, Zhao ^{[4
]}

机构：

[1] Elan Pharmaceut, Dept Med Chem, San Francisco, CA 94080 USA

[2] Elan Pharmaceut, Dept Mol Design, San Francisco, CA 94080 USA

[3] Elan Pharmaceut, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA

[4] Elan Pharmaceut, Dept Assay Dev, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 07期

关键词：

LRRK2; Parkinson's; Inhibition; Kinase; Treatment; Discovery; Wild-type; G2019S mutant; Phosphorylation; SAR; Activity; Selectivity; Bioisostere; Hinge; HTS; Oxidative metabolism; Binding mode; Synthesis; CENTER-DOT-LICL; PARKINSONS-DISEASE; HETEROAROMATICS; AROMATICS; ZINCATION; TARGETS; BINDING;

D O I：

10.1016/j.bmcl.2013.02.043

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [1,2,4]triazolo[4,3-b]pyridazines that are potent against both wild-type and mutant LRRK2 kinase activity in biochemical assays and show an unprecedented selectivity towards the G2019S mutant. A structural rational for the observed selectivity is proposed. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：1967 / 1973

页数：7

共 50 条

[41] Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives
Hu, Jiarui
Zhang, Dan
Tian, Keyue
Ren, Changyu
Li, Heng
Lin, Congcong
Huang, Xiaoli
Liu, Jie
Mao, Wuyu
Zhang, Jifa
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 256
[42] The development of CNS-active LRRK2 inhibitors using property-directed optimisation
Kavanagh, Madeline E.
Doddareddy, Munikumar Reddy
Kassiou, Michael
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (13) : 3690 - 3696
[43] Inhibitory role of peroxiredoxin 2 in LRRK2 kinase activity induced cellular pathogenesis
Yan, Kang
Zhang, Wenfeng
Han, Xu
Chang, Fei
Liu, Yongjian
JOURNAL OF BIOMEDICAL RESEARCH, 2020, 34 (02): : 103 - 113
[44] Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756)
Deng, Xianming
Gray, Nathanael S.
EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (06) : 709 - 713
[45] Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology
Zhao, Jing
Hermanson, Spencer B.
Carlson, Coby B.
Riddle, Steven M.
Vogel, Kurt W.
Bi, Kun
Nichols, R. Jeremy
BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1158 - 1162
[46] Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors
Estrada, Anthony A.
Sweeney, Zachary K.
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (17) : 6733 - 6746
[47] Effect of leucine-rich repeat kinase 2 (LRRK2) on protein synthesis
Kim, Hyejung
Son, Ilhong
Seol, Wongi
ANIMAL CELLS AND SYSTEMS, 2018, 22 (01) : 15 - 21
[48] The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors
Smith, Garrick P.
Badolo, Lassina
Chell, Victoria
Chen, I-Jen
Christensen, Kenneth Vielsted
David, Laurent
Daechsel, Justus Alfred
Hentzer, Morten
Herzig, Martin Christian
Mikkelsen, Gitte Kobberoe
Watson, Stephen P.
Williamson, Douglas S.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (18) : 4500 - 4505
[49] Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2
Schmidt, Sven H.
Weng, Jui-Hung
Aoto, Phillip C.
Boassa, Daniela
Mathea, Sebastian
Silletti, Steve
Hu, Junru
Wallbott, Maximilian
Komives, Elizabeth A.
Knapp, Stefan
Herberg, Friedrich W.
Taylor, Susan S.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (23)
[50] Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation
Hermanson, Spencer B.
Carlson, Coby B.
Riddle, Steven M.
Zhao, Jing
Vogel, Kurt W.
Nichols, R. Jeremy
Bi, Kun
PLOS ONE, 2012, 7 (08):

← 1 2 3 4 5 →